New Pill Significantly Extends Survival for Pancreatic Cancer Patients
A daily medication could potentially double survival rates in patients battling one of the most lethal forms of cancer, according to a groundbreaking clinical trial. Experts are calling this a significant breakthrough in cancer treatment.
Currently, options for treating pancreatic cancer are quite limited, with many existing therapies offering little to no benefit. Researchers have long been on the hunt for effective treatments since this cancer is often diagnosed at an advanced stage, with over half of those affected receiving their diagnosis only after it has spread.
At a major global cancer conference, professionals are celebrating the introduction of a novel drug named daraxonrasib, which they believe may revolutionize treatment approaches.
Data from a trial involving 500 patients with spreading pancreatic cancer showed that this pill effectively doubled survival duration while causing fewer side effects than traditional chemotherapy. These findings were shared at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
Patients using the drug had a median survival of 13.2 months, compared to about 6.6 to 6.7 months for those undergoing chemotherapy.
Dr. Rachna Shroff, chief of oncology at the University of Arizona Cancer Center and an expert in gastrointestinal cancers, emotionally reacted to the study’s results. “These findings could change the landscape of treatment,” she remarked, emphasizing the unprecedented survival that could result from this drug.
When she first read the trial’s outcomes, she felt overwhelmed. “After years of treating pancreatic cancer, I literally cried in clinic. This research is monumental for our patients, and I applaud the trial’s investigators,” she shared.
Dr. Julie Gralow, ASCO’s chief medical officer, echoed the sentiment, labeling it a “gamechanger.” She described the study’s success as akin to hitting a grand slam in baseball.
Daraxonrasib functions by targeting a specific protein, Kras, commonly associated with almost all cases of pancreatic cancer. The drug essentially blocks Kras from sending growth signals to cancer cells, helping to halt the disease’s progression.
Kras belongs to a family of genes linked to the continuous growth and division of cancer cells, which can lead to further development and spread of cancer. A mutation in the Kras gene is present in over 90% of patients diagnosed with pancreatic ductal adenocarcinoma (mPDAC).
This new approach, categorized as a Ras(On) multi-selective inhibitor, allows for the shutting down of Kras proteins, regardless of the specific mutation type involved.
Shroff remarked, “The quest to target Kras has long been seen as the holy grail in treating pancreatic cancer, and this study proves that it can indeed be done effectively.”
Paula Hanford, chief executive of Pancreatic Cancer Action, emphasized the significance of this discovery. She pointed out that, for too long, individuals diagnosed with this cancer faced a bleak outlook with minimal treatment options. The prospect of nearly doubling survival times is very encouraging for patients and their families.
Anna Jewell, from Pancreatic Cancer UK, expressed her excitement over the findings, stressing that this drug provides patients with more valuable time with loved ones by targeting Kras mutations.
However, she pointed out that the next critical step lies in ensuring patients have access to such innovative treatments, especially considering that many pancreatic cancer patients do not survive beyond three months post-diagnosis.
“We need to do everything possible to make these promising treatments available,” she urged, highlighting the priceless nature of additional time with loved ones.
Experts at the conference shared optimism that advancements in targeting Ras genes might lead to breakthroughs in treating other forms of cancer as well, including lung and colon cancers.
